Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P43631
UPID:
KI2S2_HUMAN
Alternative names:
CD158 antigen-like family member J; NK receptor 183 ActI; Natural killer-associated transcript 5; p58 natural killer cell receptor clone CL-49
Alternative UPACC:
P43631; Q14955; Q6H2G9
Background:
Killer cell immunoglobulin-like receptor 2DS2 (KIR2DS2) serves as a receptor on natural killer (NK) cells for HLA-C alleles, playing a pivotal role in the regulation of NK cell activity. Known by alternative names such as CD158 antigen-like family member J and NK receptor 183 ActI, KIR2DS2 is integral in the immune response, distinguishing between healthy cells and those presenting abnormalities.
Therapeutic significance:
Understanding the role of Killer cell immunoglobulin-like receptor 2DS2 could open doors to potential therapeutic strategies. Its involvement in the activation of NK cells suggests its potential in enhancing immune responses against malignancies and viral infections.